Bioactivation of 2,3-Diaminopyridine-Containing Bradykinin B1 Receptor Antagonists: Irreversible Binding to Liver Microsomal Proteins and Formation of Glutathione Conjugates
- 25 May 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 18 (6) , 934-945
- https://doi.org/10.1021/tx0500427
Abstract
The 2,3-diaminopyridine (DAP) moiety was found to represent a core structure essential for the potency of a new series of human bradykinin B(1) receptor antagonists. However, incubation of (14)C-labeled 2,3-DAP derivatives with rat and human liver microsomes resulted in substantial irreversible binding of radioactive material to macromolecules by a process that was NADPH-dependent. Trapping the reactive species with GSH led to significant reduction of the irreversible binding of radioactivity, with concomitant formation of abundant GSH adducts. One type of thiol adducts (detected in both human and rat liver microsomes), resulting from addition of 305 Da to the parent compound, was observed with all 2,3-DAP compounds. These adducts also were detected in rat hepatocyte incubates, as well as in rat bile, following intravenous administration of 2,3-DAPs. Formation of the conjugates appeared to involve modification of the DAP ring, based upon mass spectral analysis of a number of representative GSH adducts; this was corroborated by detailed LC NMR analysis of one compound. Formation of this type of GSH conjugate was markedly reduced when the 2-amino methyl group linking the 2,3-DAP and the biphenyl moiety was replaced with an ether oxygen atom. It is postulated, therefore, that oxidation of the 2-amino group serves as a key step leading to the formation of reactive species associated with the DAP core. In addition, this step appears to be mediated primarily by P450 3A, as evidenced by the marked decrease in both the irreversible binding of radioactivity and the formation of the GSH adducts in human liver microsomes following treatment with ketoconazole and monoclonal antibodies against P450 3A. A mechanism for the bioactivation of 2,3-DAP is proposed wherein oxidation (dehydrogenation or N-hydroxylation followed by dehydration) of the 2-amino group, catalyzed by P450 3A, results in the formation of a highly electrophilic species, pyridine-2,3-diimine.Keywords
This publication has 9 references indexed in Scilit:
- 2,3-Diaminopyridine Bradykinin B1 Receptor AntagonistsJournal of Medicinal Chemistry, 2004
- Drug−Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and DevelopmentChemical Research in Toxicology, 2003
- Localization of B1 bradykinin receptor mRNA in the primate brain and spinal cord: An in situ hybridization studyJournal of Comparative Neurology, 2003
- Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniquesJournal of Mass Spectrometry, 2003
- Acyl Glucuronidation and Glucosidation of a New and Selective Endothelin ETA Receptor Antagonist in Human Liver MicrosomesDrug Metabolism and Disposition, 2003
- The bradykinin B1 receptor antagonist B9858 inhibits a nociceptive spinal reflex in rabbitsCanadian Journal of Physiology and Pharmacology, 2002
- Expression of B1 and B2 bradykinin receptor mRNA and their functional roles in sympathetic ganglia and sensory dorsal root ganglia neurones from wild-type and B2 receptor knockout miceNeuropharmacology, 1997
- Kinin B1 receptors: a reviewImmunopharmacology, 1995
- [5] Isolation of microsomal subfractions by use of density gradientsPublished by Elsevier ,1978